Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Frye

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|May 23, 1998
Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measureR F Frye, A Adedoyin, K Mauro, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 14, 1999
Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patientsH J Manley, G R Bailie, R D Asher, et al.
Clinical Pharmacology and Therapeutics|November 14, 1997
Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymesR F Frye, G R Matzke, A Adedoyin, et al.
British Journal of Clinical Pharmacology|October 24, 2006
Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activityN K Zgheib, R F Frye, T S Tracy, et al.
Journal of Clinical Pharmacology|April 10, 1999
DHEA and DHEA-S: a reviewP D Kroboth, F S Salek, A L Pittenger, et al.
British Journal of Clinical Pharmacology|September 1, 1996
The effect of age on the pharmacokinetics of the opioid antagonist nalmefeneR F Frye, G R Matzke, N S Jallad, et al.
Pharmacotherapy|March 11, 2000
Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activityG R Matzke, R F Frye, J J Early, et al.
British Journal of Clinical Pharmacology|December 21, 2004
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjectsM W Hruska, J A Amico, T Y Langaee, et al.
Journal of Clinical Pharmacology|February 1, 1996
The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefeneG R Matzke, R F Frye, A C Alexander, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsoneJ M Hutzler, R F Frye, K R Korzekwa, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|May 23, 1998
Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measureR F Frye, A Adedoyin, K Mauro, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 14, 1999
Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patientsH J Manley, G R Bailie, R D Asher, et al.
Clinical Pharmacology and Therapeutics|November 14, 1997
Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymesR F Frye, G R Matzke, A Adedoyin, et al.
British Journal of Clinical Pharmacology|October 24, 2006
Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activityN K Zgheib, R F Frye, T S Tracy, et al.
Journal of Clinical Pharmacology|April 10, 1999
DHEA and DHEA-S: a reviewP D Kroboth, F S Salek, A L Pittenger, et al.
British Journal of Clinical Pharmacology|September 1, 1996
The effect of age on the pharmacokinetics of the opioid antagonist nalmefeneR F Frye, G R Matzke, N S Jallad, et al.
Pharmacotherapy|March 11, 2000
Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activityG R Matzke, R F Frye, J J Early, et al.
British Journal of Clinical Pharmacology|December 21, 2004
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjectsM W Hruska, J A Amico, T Y Langaee, et al.
Journal of Clinical Pharmacology|February 1, 1996
The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefeneG R Matzke, R F Frye, A C Alexander, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsoneJ M Hutzler, R F Frye, K R Korzekwa, et al.
Pageof 5